Celltrion
셀트리온 · 068270
Health Care Pharmaceuticals · KOSPI
Market cap US$30.2B (₩41.7T)
Overview
Celltrion is a Korean biopharmaceutical company that develops and makes biosimilars, which are more affordable versions of biologic medicines whose patents have expired.
It produces antibody-based treatments for cancers and autoimmune conditions and supplies them to markets around the world, often through partners. The company also works on its own novel drugs and runs large biologics manufacturing facilities in Korea.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$1.6B
- FY2024US$2.6B
- FY2025US$3B
Operating profit
- FY2023US$472.1M
- FY2024US$356.5M
- FY2025US$846.7M
Net income
- FY2023US$391.1M
- FY2024US$303.5M
- FY2025US$747.5M
Key ratios (FY2025)
Why it matters
Biosimilars are follow-on versions of biologic drugs, a different business from the small-molecule generics most people picture.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?